{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Squamous+Non-Small+Cell+Lung+Carcinoma&page=13", "query": { "condition": "Non-Squamous Non-Small Cell Lung Carcinoma", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 751, "total_pages": 76, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Squamous+Non-Small+Cell+Lung+Carcinoma&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Squamous+Non-Small+Cell+Lung+Carcinoma&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T22:51:10.601Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Squamous Cell Head and Neck Cancer", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Other Tumors With EGFR Dependence" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2011-10", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451632" }, { "nct_id": "NCT00055887", "title": "Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "efaproxiral", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" }, { "name": "radiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Spectrum Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2002-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-10", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Coeur d'Alene, Idaho • Lexington, Kentucky + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055887" }, { "nct_id": "NCT01096381", "title": "Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Cardiovascular Complications", "Colorectal Cancer", "Fallopian Tube Cancer", "Head and Neck Cancer", "Lung Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2010-03", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2012-02-27", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01096381" }, { "nct_id": "NCT00066651", "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Fallopian Tube Cancer", "Head and Neck Cancer", "Lung Cancer", "Malignant Mesothelioma", "Ovarian Cancer", "Pancreatic Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "SS1(dsFv)-PE38 immunotoxin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066651" }, { "nct_id": "NCT00309998", "title": "Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "70 Years to 120 Years" }, "enrollment_count": 50, "start_date": "2005-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309998" }, { "nct_id": "NCT01294306", "title": "MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenosquamous Lung Carcinoma", "Bronchioloalveolar Carcinoma", "Large Cell Lung Carcinoma", "Lung Adenocarcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Squamous Cell Lung Carcinoma" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-02", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-11-29", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 7, "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01294306" }, { "nct_id": "NCT00438204", "title": "Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2006-05", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • Detroit, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00438204" }, { "nct_id": "NCT04267848", "title": "Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Lung Non-Small Cell Squamous Carcinoma", "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Observation Activity", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1210, "start_date": "2020-06-16", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 1150, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04267848" }, { "nct_id": "NCT00287963", "title": "Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "vinorelbine tartrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 18, "start_date": "2004-02", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287963" }, { "nct_id": "NCT03409614", "title": "Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "REGN2810", "type": "DRUG" }, { "name": "REGN2810/chemo/ipi", "type": "DRUG" }, { "name": "Chemotherapy", "type": "OTHER" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 789, "start_date": "2018-03-06", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-10-23T22:51:10.601Z", "location_count": 9, "location_summary": "Rancho Mirage, California • Riverside, California • Whittier, California + 6 more", "locations": [ { "city": "Rancho Mirage", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Orange City", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03409614" } ] }